Skip to content

REVAPREVENT

Active Private limited companyfounded 2010active for 15 yearsKoning Albert I-laan 25, 8800 RoeselareKBO/BCE: BE 0832.428.660

Lifetime

15 annual accounts with figures on one time axis
peak of €503,137 in 2024
€268,209▼ 46.7%
peak of €345,014 in 2024
€181,088▼ 47.5%
peak of €1.5m in 2024
€1.5m▼ 1.0%
€57,899▼ 35.7%
peak of 0.7 FTE in 2011
0 FTE 
Board3 names since 2010
3 directors and 2 others
Documentsfilings and deeds
16-07-202615 days before the deadline
2025abbreviated format
Gross margin from €503,137 to €268,209Result from €345,014 to €181,088Dividend €196,498Debts from €90,013 to €57,899

Key points

from the 2025 annual accounts

Equity

€1.5m ▼ 1.0%
1.52024+0.2Profit-0.2Dividend1.52025

REVAPREVENT paid out €196,498 in dividends. That is 109% of the 2025 profit.

Result

€181,088 ▼ 47.5%
€345,0002024€181,0002025

The result fell in 2025 from €345,014 to €181,088.

Turnover

≈ €400,000 estimated

The abbreviated format states no turnover.

Liquidity

28.41 was 18.53 in 2024

Short-term debts fell from €87,127 to €55,299.

Filings

15 annual accounts since 2011
AprilJune31 JulyOctober201520202025

The last five annual accounts were filed 13 to 33 days before the end of the period.

Position in the sector

96.3%

Higher solvency than 94% of companies in human health. Sector median 59.4% · 2,821 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 17,816 companies had the same profile as REVAPREVENT has now. Each dot stands for 45 companies, two years later.

96.5%
were still trading
3.2%
stopped another way
0.3%
went bankrupt
  • Small
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 17,816 companies, not a prediction for REVAPREVENT. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Manager, since 17-12-2010
Director, since 17-12-2010
Director, , since 02-01-2011
  • 115 sharesdeed of 26-01-2018
  • 5 sharesdeed of 26-01-2018
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0832428660
(director) and (director) change roles acts as permanent representative · Gazette deed
Capital decrease of €202,500 to €18,600 The capital fell from €221,100 to €18,600, cancelling 134 shares · holds 115 shares · holds 5 shares · Gazette deed
appointed as manager acts as permanent representative · General meeting of 02-01-2011 · Gazette deed
All 27 events

Comparable companies

same main activity, similar in size and age
Company
REVAPREVENT Roeselare €1.6m €268,209 96.3% 0
Dokter Jens Deckers,neurochirurgie Hasselt €1.4m €241,260 88.4% 0
DR.GREGORY CLEMENT De Haan €1.8m €261,171 20.1% 0
DOKTER STEVEN VISSERS Lier €1.3m €288,318 78.2% 0
ELANIE Vosselaar €1.4m €330,697 52.8% 0
DR. JACOBS SIGRID - OPHTALMOLOOG Sint-Gillis-Waas €1.1m €286,771 58.4% 0.2
Dokter Van Genechten Antwerp €1.9m €218,128 59.9% 0

These companies have the same main activity as REVAPREVENT: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €1.1m and €1.9m, founded between 2005 and 2011.

Official details

Source: KBO
Status
Active since 17-12-2010Normal situation
Activity
Specialist medical practiceNACE 86220and 1 other
Establishment unit
2.195.020.8198800 Roeselare, since 01-01-2011
Financial year end
31 December
Peppol
Reachable since 18-11-2025
Company details

Annual accounts 2025

€1.6m▼ 2.9%
Filing
Filed on 16-07-2026, 15 days before the end of the filing period
Financials

Insights on REVAPREVENT

REVAPREVENT files the abbreviated format. That format states no turnover. The gross margin fell from €389,397 in 2011 to €268,209 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about REVAPREVENT

What is the company number of REVAPREVENT?
The company number of REVAPREVENT is 0832.428.660. The VAT number is the same number with BE in front: BE 0832.428.660.
Where is REVAPREVENT based?
The registered office is at Koning Albert I-laan 25, 8800 Roeselare.Company details
What does REVAPREVENT do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of REVAPREVENT?
REVAPREVENT is a private limited company (BV).
When was REVAPREVENT founded?
REVAPREVENT was founded on 17-12-2010.
Is REVAPREVENT still active?
Yes, REVAPREVENT is an active enterprise in the KBO register.
What is the turnover of REVAPREVENT?
The turnover in financial year 2025 is ≈ €400,000. This figure is estimated from the gross margin of €268,209 and 31 comparable companies (NACE 86220). It probably lies between €360,000 and €560,000.Financials
Is REVAPREVENT profitable?
In financial year 2025, REVAPREVENT made a profit of €181,088.
Where can I find the annual accounts of REVAPREVENT?
REVAPREVENT filed 15 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of REVAPREVENT due?
REVAPREVENT must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.